- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04899245
ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - COVID-19 Testing in School With Children and Staff
ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - SARS-CoV-2 Testing in School With Children and Staff
The Coronavirus Disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, is a worldwide pandemic that has resulted in large-scale quarantines in cities, states, and countries throughout the world. SARS-CoV-2 is a respiratory virus that is most commonly spread via contact with infective respiratory droplets and aerosols produced by coughing, sneezing, talking, and singing.
Children with medical complexity (CMC), i.e., children with multiple severe chronic conditions, high resource use, severe functional limitations, and substantial family-identified service needs, are a medically vulnerable population for the development of severe COVID-19. Deciding to send CMC to school poses a major dilemma to families wanting to minimize severe COVID-19 risk. School personnel also face risks when CMC attend school. Despite these challenges, achieving in-person school attendance is critical for CMC. Compared to non-CMC, academic and social development for most CMC hinges on being at school. Severe intellectual and developmental disability impairs one's ability to engage with online platforms. Health-promoting services delivered at school, e.g., physical, occupational, and speech therapy, are likely less effective when delivered virtually. Parents of CMC, already disproportionately unemployed due to their child's care needs, experience added employment strain when their child is out of school.
The study objective is to increase the safe return to school for CMC by 1) evaluating the feasibility of school-based COVID-19 testing strategies and 2) identifying parent and staff perceptions of testing and school attendance. A related study (ReSET Aim 1a, NCT04895085) will evaluate the same factors in home-based testing strategies in CMC exclusively.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792-4108
- University of Wisconsin School of Medicine and Public Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Parents and staff must be at least 18 years of age.
- Staff must have a classroom role (e.g., teacher, aide, playground assistant)
- Parents and staff must be proficient in English.
- Parents and staff must have access to a web-enabled device (phone, tablet, or computer).
- Staff, parent and child must be residents of Wisconsin.
- Parent/child must be enrolled at WECP for the 2021 and/or 2022 school year.
Exclusion Criteria:
- Failure to meet all inclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: School Staff
50 school staff from Waisman Early Childhood Program (WECP) will be recruited to participate in this study. School staff will send a letter to all WECP staff inviting them to participate. Staff new to the school or who initially decline participation and then reconsider may join at any time. Additionally, staff who are vaccinated will be asked to participate in testing. |
BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more. |
|
Experimental: Parent/Child with Children with medical complexity (CMC)
65 children and their parents will be recruited to participate. School staff will send a letter to all parents with children enrolled in the Waisman Early Childhood Program (WECP) inviting them to participate. Families new to the school or who initially decline participation and then reconsider may join at any time. Participants will also be offered the option of as needed symptomatic home testing. Additionally, parents who are vaccinated will be asked to participate in testing. Siblings may be enrolled in the study. |
BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Protocol Uptake: Number of Children and Staff Consented Compared to Number of Approached
Time Frame: Study duration (up to 21 months)
|
Feasibility of school based COVID-19 testing will be evaluated by protocol uptake. Data will be retrieved from the study log. Two data limitations to note:
|
Study duration (up to 21 months)
|
|
Change in COVID Test Rate at School: Number of Total Child and Staff Tests Completed as Compared to Number of Tests Expected
Time Frame: Every week up to 21 months
|
|
Every week up to 21 months
|
|
Change in Symptomatic Test Rate: Number of Symptomatic Tests Completed
Time Frame: Study duration (up to 21 months)
|
Data will be retrieved from study log.
|
Study duration (up to 21 months)
|
|
Change in Positive Rate: Number of Positive COVID-19 Tests Compared to Total Number of Tests Performed
Time Frame: Study duration (up to 21 months)
|
Data will be retrieved from study log.
|
Study duration (up to 21 months)
|
|
Change in False-positive Rate: Number of Negative Confirmatory Polymerase Chain Reaction (PCR) as Compared to Total PCR Run for COVID-19 Testing
Time Frame: Study duration (up to 21 months)
|
Data will be retrieved from study log. All children and staff (n = 71) were included in this outcome. However, participants were not required to and were sometimes unable to complete a confirmatory PCR test after a positive in-home rapid test. This explains the difference between the number of positive at-home COVID-19 tests and the number of PCR tests. Some participants completed multiple confirmatory PCR tests over the study time frame. This explains why the PCR quantity is greater than the number of participants. |
Study duration (up to 21 months)
|
|
Caregiver Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Susceptibility: School Takes Precautions
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
The following question from the Participant's perceived susceptibility survey will be answered dichotomously and presented qualitatively:
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Susceptibility: Likely to Get COVID-19
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Following questions from the Participant's perceived susceptibility survey will be answered dichotomously (agree or disagree) and presented qualitatively.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Change in Percentage of Caregivers for Perceived Severity Survey Question: Health Severely Affected
Time Frame: 15 month, 18 month, 21 month, 24 month
|
Parent survey perceived severity construct variables will include:
|
15 month, 18 month, 21 month, 24 month
|
|
Change in Percentage of Caregivers to the Perceived Severity Survey Question: Health Permanently Reduced
Time Frame: 15 month, 18 month, 21 month, 24 month
|
Parent survey perceived severity construct variables will be:
|
15 month, 18 month, 21 month, 24 month
|
|
Change in Percentage of Caregivers to the Perceived Severity Survey Question: Grave Health Consequences
Time Frame: 15 month, 18 month, 21 month, 24 month
|
Parent survey perceived severity construct variables will be:
|
15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Motivation for Child to Attend School (Quite a Bit / a Great Deal vs Not)
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Participants will answer the following survey question in quite a bit / a great deal vs not:
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Perceived Benefits to Child Attending School: Important to Health
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Parent survey perceived benefits construct survey will be having 6 questions ranging from benefits to child's overall health, therapy needs, impact on family. Survey will be analyzed qualitatively.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Perceived Benefits to Child Attending School: In-person Schooling
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Parent survey perceived benefits construct survey will be having 6 questions ranging from benefits to child's overall health, therapy needs, and impact on family. Survey will be analyzed qualitatively.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Perceived Benefits to Child Attending School: Therapy Needs
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Parent survey perceived benefits construct survey will be having 6 questions ranging from benefits to child's overall health, therapy needs, impact on family. Survey will be analyzed qualitatively.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Perceived Benefits to Child Attending School: Positive for Family
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Parent survey perceived benefits construct survey will be having 6 questions ranging from benefits to child's overall health, therapy needs, impact on family. Survey will be analyzed qualitatively.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Perceived Benefits to Child Attending School: Positive for Staff
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Parent survey perceived benefits construct survey will be having 6 questions ranging from benefits to child's overall health, therapy needs, impact on family. Survey will be analyzed qualitatively.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Perceived Benefits to Child Attending School: Keep Jobs
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Parent survey perceived benefits construct survey will be having 6 questions ranging from benefits to child's overall health, therapy needs, impact on family. Survey will be analyzed qualitatively.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Barriers to School Attendance: Number of People
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Survey will have following questions which will be answered dichotomously very/extremely [comfortable] vs not.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Barriers to School Attendance: Proximity
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Survey will have following questions which will be answered dichotomously very/extremely [comfortable] vs not.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Barriers to School Attendance: PPE
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Survey will have following questions which will be answered dichotomously very/extremely [comfortable] vs not.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Barriers to School Attendance: Testing
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Survey will have following questions which will be answered dichotomously very/extremely [comfortable] vs not.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Barriers to School Attendance: Following Recommendations
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Survey will have following questions which will be answered dichotomously very/extremely [comfortable] vs not.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Barriers to School Attendance: Transportation
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Survey will have following questions which will be answered dichotomously very/extremely vs not.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Barriers to School Attendance: Wash
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Survey will have following questions which will be answered dichotomously very/extremely vs not.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Barriers to School Attendance: Close Contact
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Survey will have following questions which will be answered dichotomously very/extremely [comfortable] vs not.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Barriers to School Attendance: Masking
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Survey will have following questions which will be answered dichotomously very/extremely vs not.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N)
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Participants will answer the following survey question in Yes/No:
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Option and Practice: School Attendance
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Participant will be asked the attendance question in survey. It will be answered in Yes/No.
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
|
Caregiver Change in Option and Practice: Option to Attend School
Time Frame: Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Participant will be asked the attendance question in survey. It will be answered in Yes/No
|
Baseline, 3 month, 6 month, 9 month, 15 month, 18 month, 21 month, 24 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ryan Coller, MD, MPH, University of Wisconsin, Madison
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-0488
- 2022-0810 (UW Madison)
- A536771 (Other Identifier: UW Madison)
- SMPH/PEDIATRICS (Other Identifier: UW Madison)
- Protocol Version 7/11/22 (Other Identifier: UW Madison)
- 1OT2HD107558-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
PfizerActive, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionUnited States
-
Shanghai Public Health Clinical CenterNot yet recruiting
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RecruitingPost COVID-19 Condition | Post COVID-19 | Post COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID-19 Condition (PCC)Germany
-
PfizerRecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionBelgium
-
ModeX Therapeutics, An OPKO Health CompanyRecruitingCOVID -19 | COVID-19 (Prevention)United States
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRecruitingFatigue | Post-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19 | Long-COVID | Post-COVID ConditionCanada
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
RSUP PersahabatanCompletedPost COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID Syndrome Long CovidIndonesia
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
Clinical Trials on BinaxNOW Rapid Antigen System
-
University of Wisconsin, MadisonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCOVID-19 | Children With Medical Complexity (CMC)United States
-
Nanogen, Inc.Suspended
-
Salem Anaesthesia Pain ClinicRecruiting
-
Elizabeth Glaser Pediatric AIDS FoundationFind; Kiambu CountyCompletedSevere Acute Respiratory Syndrome Coronavirus 2 InfectionKenya
-
Mahidol UniversityChulalongkorn University; Ministry of Health, Thailand; Yuvabadhana foundation; Zero COVID ThailandCompletedCoronavirus Infections | Covid19 | SARS-CoV-2 | Community TransmissionsThailand
-
Mach-E B.V.Completed
-
University of British ColumbiaProvidence Health & Services; Vancouver Airport Authority; WestJet Airlines; KLM...Completed
-
Institute of Tropical Medicine, BelgiumWithdrawn
-
National Institute of Respiratory Diseases, MexicoCompleted